Welcome to Targos

A Leader in Customer-Oriented Biomarker Services

Targos core service business is to provide highly standardized development and application of clinical biomarkers for the international pharmaceutical and diagnostic industry. The company has supported more than 100 international clinical trials since 1999, which have led to the successful approval of several targeted therapies and IVDs for our customers. The expert team of on-site clinical pathologists operates in a professional environment of project management, logistics, data and quality management. Targos also supports the introduction of new Companion Diagnostic assays into the market.

Targos is a fully GCP-compliant central laboratory that is inspected by the U.S. Food and Drug Administration (FDA). As of June 2013, Targos Molecular Pathology GmbH has met all applicable standards for accreditation and is accredited by the College of American Pathologists (CAP). As of January 2014 Targos is enrolled in the CLIA program.

A Genomics-Based Classification of Human Lung Tumors

The Clinical Lung Cancer Genome Project (CLCGP) and Network Genomic Medicine (NGM)

Sci Transl Med. 2013 Oct 30;5(209):209ra153
http://stm.sciencemag.org/content/5/209/209ra153.abstract
Study Leaders: Reinhard Büttner, Jürgen Wolf and and Roman K. Thomas
Prof. Reinhard Büttner is Co-Founder and Chief Scientific Officer of Targos